scispace - formally typeset
P

Paul D. Piehowski

Researcher at Pacific Northwest National Laboratory

Publications -  95
Citations -  4663

Paul D. Piehowski is an academic researcher from Pacific Northwest National Laboratory. The author has contributed to research in topics: Proteomics & Proteome. The author has an hindex of 28, co-authored 79 publications receiving 2741 citations. Previous affiliations of Paul D. Piehowski include Environmental Molecular Sciences Laboratory & Pennsylvania State University.

Papers
More filters
Journal ArticleDOI

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

David J. Clark, +224 more
- 31 Oct 2019 - 
TL;DR: A large-scale proteogenomic analysis of ccRCC is reported to discern the functional impact of genomic alterations and provides evidence for rational treatment selection stemming fromccRCC pathobiology.
Journal ArticleDOI

Nanodroplet processing platform for deep and quantitative proteome profiling of 10-100 mammalian cells.

TL;DR: A robotically controlled chip-based nanodroplet processing platform is established and its ability to profile the proteome from 10–100 mammalian cells is demonstrated, illustrating the application of nanoPOTS for spatially resolved proteome measurements from clinical tissues.
Journal ArticleDOI

The human body at cellular resolution: the NIH Human Biomolecular Atlas Program

Michael Snyder, +133 more
- 09 Oct 2019 - 
TL;DR: The NIH Common Fund Human Biomolecular Atlas Program (HuBMAP) intends to develop a widely accessible framework for comprehensively mapping the human body at single-cell resolution by supporting technology development, data acquisition, and detailed spatial mapping.
Journal ArticleDOI

Proteogenomic Characterization of Endometrial Carcinoma.

Yongchao Dou, +219 more
- 20 Feb 2020 - 
TL;DR: A comprehensive proteogenomic characterization of endometrial carcinomas revealed possible new consequences of perturbations to the p53 and Wnt/β-catenin pathways, identified a potential role for circRNAs in the epithelial-mesenchymal transition, and provided new information about proteomic markers of clinical and genomic tumor subgroups, including relationships to known druggable pathways.